首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備 DDS

市場調查報告書

商品編碼

1316273

全球控釋給藥市場 - 2023-2030 年

Global Controlled Release Drug Delivery Market - 2023-2030

出版日期: 2023年07月27日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概述

2022 年，全球控釋給藥市場規模達到509 億美元，預計到2030 年將實現利潤豐厚的成長，達到1013 億美元。在預測期內（2023-2030 年），全球控釋給藥市場預計將呈現9.2% 的複合年成長率。

控釋系統可實現藥物的長期持續、有序釋放。這種調節釋放有助於將治療藥物濃度保持在適當範圍內，最大限度地提高療效。它可以減少給藥次數，保證持續供藥，從而提高患者的依從性，達到更好的治療效果。

此外，由於製藥公司積極應對不斷變化的市場需求，並持續投資開發控釋給藥方法，因此極大地促進了需求。

市場動態

老年人口和兒童人口的增加將推動市場成長

全球老年人口和兒童人口的不斷成長是推動市場擴大的主要原因之一，這主要是由於這些年齡段的人普遍不遵從處方治療。老年人的身體、精神和生物功能受損，影響了他們的用藥。

例如，世衛組織指出，所有國家在確保其衛生和社會系統做好準備利用這一人口結構轉變方面都面臨重大挑戰。到2050 年，80% 的老年人將生活在中低收入國家。人口老齡化的速度大大高於過去。

2020 年，60 歲及以上人口的數量將超過5 歲以下的年輕人。從2015 年到2050 年，全球60 歲以上人口的比例將增加近一倍，從12%增至22%。因此，不斷成長的老年人口將有助於推動市場擴張。

主要公司不斷加強的計劃和戰略也將推動市場成長

據預測，主要企業為應對控釋給藥不斷成長的需求而開展的活動和實施的戰略也將推動市場擴張。例如，2020 年10 月，德國贏創工業集團（Evonik Industries AG）推出了一種口服給藥技術Eudratec Fasteric，該技術可提高口服藥物的腸道吸收率，其靶點位於吸收窗口較窄的小腸上段。

此外，該技術可使用傳統器械快速高效地加工，並與多種口服劑型兼容，包括多顆粒、片劑和膠囊。市場將因上述因素而擴大。

缺乏按需釋放技術將阻礙市場成長

開發按需控釋給藥系統在技術上具有挑戰性。它需要整合複雜的機制，以觸發藥物釋放來響應特定的刺激或外部訊號。設計這種能精確控製藥物釋放速率和劑量的系統非常複雜，通常需要先進的材料和工程技術。

由於需要專門的材料、技術和製造程序，開發按需控釋系統的成本可能很高。此外，這些系統的複雜性可能會增加生產成本，使其更難以負擔和廣泛使用。因此，上述因素將限制市場的成長。

COVID-19 影響分析

COVID-19 大流行對控釋給藥領域產生了積極和消極的影響。由於對COVID-19 疫苗的迫切需求，控釋疫苗給藥系統的開發受到了極大重視。這些系統旨在提高疫苗療效、減少所需劑量並改善患者的依從性。

人們一直在努力開發長效疫苗製劑，以提供持續的免疫反應，並消除對頻繁加強劑的需求。大流行導致醫療保健和製藥研究方面的資金和投資增加。這為控釋給藥系統的開發創造了新的機會。

俄烏戰爭影響分析

據估計，俄烏衝突對全球控釋給藥市場的影響不大，原因是該地區的主要市場參與者較少。不過，在預測期內，原料進出口的影響預計對全球控釋給藥市場的成長影響不大。

Market Overview

The global controlled release drug delivery market reached US$ 50.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 101.3 billion by 2030. The global controlled release drug delivery market is expected to exhibit a CAGR of 9.2% during the forecast period (2023-2030).

Controlled release systems enable the sustained and regulated release of medications over a long period of time. This regulated distribution helps to keep therapeutic medication concentrations within the appropriate range, maximising therapy efficacy. It can increase patient compliance by reducing drug administration frequency and guaranteeing continuous drug supply, resulting in better therapeutic outcomes.

Additionally, pharmaceutical companies, who operate in a fiercely competitive and fragmented industry, have greatly boosted demand as a result of their proactive response to evolving market demands and continued investments in developing controlled-release drug delivery methods.

Market Dynamics

The Increasing Geriatric and Pediatric Population will Drive the Market Growth

The growing geriatric and paediatric population worldwide is one of the primary reasons driving market expansion, owing largely to non-adherence to prescription regimens, which is quite common among these age groups. Geriatric people have impaired physical, mental, and biological functioning, which affect their medication usage.

For instance, according to WHO, all countries have significant challenges in ensuring that their health and social systems are prepared to capitalise on this demographic transformation. By 2050, 80% of the elderly will live in low- and middle-income countries. The population is ageing at a considerably higher rate than in the past.

In 2020, the number of persons aged 60 and more will outnumber youngsters under the age of five. Between 2015 and 2050, the fraction of the global population over the age of 60 will nearly double, from 12% to 22%. As a result, the growing senior population will aid to boost market expansion.

Raising Initiatives And Strategies By the Key Companies also Drive the Market Growth

The increased activities and strategies implemented by key players to deal with the growing demand for controlled release medicine delivery are also predicted to fuel market expansion. For instance, in October 2020, Evonik Industries AG, a German pharmaceutical company, has introduced Eudratec Fasteric, an oral drug delivery technology that improves intestinal absorption for oral drug products that target sites in the upper small intestine with a narrow absorption window.

Furthermore, it can be processed rapidly and efficiently using conventional instruments and is compatible with a wide range of oral dose forms, including multiarticulate, tablets, and capsules. The market will expand as a result of the aforementioned factors.

Lack of On-Demand Release will Hamper the Market Growth

Developing on-demand controlled release drug delivery systems is technically challenging. It requires the integration of sophisticated mechanisms to trigger drug release in response to specific stimuli or external signals. Designing such systems with precise control over drug release rates and dosages is complex and often requires advanced materials and engineering techniques.

Developing on-demand controlled release systems can be costly due to the need for specialized materials, technologies, and manufacturing processes. Additionally, the complexity of these systems may increase the production costs, making them less affordable and accessible for widespread use. Thus, above factors will restrict the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has had both positive and negative impacts on the field of controlled release drug delivery. With the urgent need for COVID-19 vaccines, there has been a significant emphasis on developing controlled release vaccine delivery systems. These systems aim to enhance vaccine efficacy, reduce the number of doses required, and improve patient compliance.

Efforts have been made to develop long-acting vaccine formulations that provide sustained immune response and eliminate the need for frequent boosters. The pandemic has led to increased funding and investment in healthcare and pharmaceutical research. This has created new opportunities for the development of controlled release drug delivery systems.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global controlled release drug delivery market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global controlled release drug delivery market growth over the forecast period.

Segment Analysis

The global controlled release drug delivery market is segmented based on release mechanism, technology, route of administration and region.

Auto-injectors/Needle-free injectors from Route of Administration Segment Aaccounts for 30.7% of Market Share Owing to Rising Novel Product Launches

During the projection period, targeted drug delivery is expected to dominate the market. This is mainly due to expanding demand, as well as a growing geriatric and paediatric population. For instance, In 2021, there were about 26.2 million children between the ages of 12 and 17 years old living in the United States. On the other hand, there were about 22.9 million children between the ages of zero and five years old in the country.

Additionally, when compared to typical delivery methods, targeted delivery systems achieve a longer therapeutic effect by delivering medications at the target site at predetermined drug release kinetics. Furthermore, the increasing number of product launches as a result of the increased benefits afforded by targeted delivery are likely to support the segment's growth.

Geographical Analysis

Europe Accounted for Approximately 27.4% of the Market Share

Due to increased R&D efforts and the presence of large pharmaceutical companies in the region. With an increase in patients suffering from chronic diseases such as cancer, diabetes, and COPD, the regional market is expected to grow steadily in the next years.

For instance, according to EUROSTAT, In 2020, cancer was the second highest cause of death in the EU, accounting for 1.2 million deaths, or 23.0% of all deaths in the EU. Cancer claimed a greater share of male mortality (24.9%) than female deaths (20.0%). As a result, the previously mentioned factors will dominate market growth.

Competitive Landscape

The major global players in the controlled release drug delivery market include: Johnson and Johnson, Coating Place, Inc, Corium International, Inc, Depomed, Inc, Pfizer, Inc, Biogen, GlaxoSmithKline, Novartis, Orbis Biosciences, Inc., Merck and Co among others.

Why Purchase the Report?

To visualize the global controlled release drug delivery market segmentation based on release mechanism, technology, route of administration and region,as well as understandkey commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of controlled release drug delivery market-level with all segments.
PDF report consists of a comprehensiveanalysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available asexcelconsisting of key products of all the major players.

The global controlled release drug delivery market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Release Mechanism
3.2. Snippet by Technology
3.3. Snippet by Route of Administration
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increase in prevalence of chronic diseases
  - 4.1.1.2. Raising initiatives and strategies by the key companies
- 4.1.2. Restraints
  - 4.1.2.1. Lack of On-Demand Release
- 4.1.3. Opportunity
  - 4.1.3.1. Developing countries with limited access to healthcare infrastructure
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Release Mechanism

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Release Mechanism
- 7.1.2. Market Attractiveness Index, By Release Mechanism
7.2. Polymer-based drug delivery system*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Activation modulated drug delivery system
- 7.3.1. Osmotic pressure activated drug delivery
- 7.3.2. Hydrodynamic pressure activated drug delivery
- 7.3.3. Vapor pressure activated drug delivery
- 7.3.4. Mechanically activated drug delivery
7.4. Chemically activated drug delivery system
- 7.4.1. pH activated drug delivery
- 7.4.2. Hydrolysis activated drug delivery
- 7.4.3. Enzyme activated drug delivery

8. ByTechnology

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.1.2. Market Attractiveness Index, By Technology
8.2. Wurster technique*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Micro encapsulation
8.4. Coacervation
8.5. Targeted delivery
8.6. Others

9. By Route of Administration

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Drug-eluting stents*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ocular implants
9.4. Auto-injectors/ Needle-free injectors
9.5. Nasal sprays
9.6. Infusion pumps
9.7. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Release Mechanism
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Release Mechanism
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Spain
  - 10.3.6.5. Italy
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Release Mechanism
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Release Mechanism
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan

Australia

10.5.6.4. Rest of Asia-Pacific

10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Release Mechanism
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Johnson and Johnson.*
- 12.1.1. Company Overview
- 12.1.2. ProductPortfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Coating Place, Inc
12.3. Corium International, Inc
12.4. Depomed, Inc
12.5. Pfizer, Inc
12.6. Biogen
12.7. GlaxoSmithKline
12.8. Novartis
12.9. Orbis Biosciences, Inc.
12.10. Merck and Co.

LIST NOT EXHAUSTIVE